» Authors » Liang-In Lin

Liang-In Lin

Explore the profile of Liang-In Lin including associated specialties, affiliations and a list of published articles. Areas
Snapshot
Articles 87
Citations 1487
Followers 0
Related Specialties
Top 10 Co-Authors
Published In
Affiliations
Soon will be listed here.
Recent Articles
1.
Yen J, Keak P, Wu C, Chen H, Gao W, Liou J, et al.
Biomed Pharmacother . 2024 Sep; 179:117395. PMID: 39241566
Core binding factor acute myeloid leukemia (CBF-AML) stands out as the most common type of adult AML, characterized by specific chromosomal rearrangements involving CBF genes, particularly t(8;21). Shikonin (SHK), a...
2.
Tien F, Yao C, Cheng-Hong Tsai X, Lo M, Chen C, Lee W, et al.
Blood Cancer J . 2024 Jan; 14(1):15. PMID: 38253683
Acute myeloid leukemia (AML) with CEBPA bZIP in-frame mutations (CEBPA) is classified within the favorable-risk group by the 2022 European LeukemiaNet (ELN-2022). However, heterogeneous clinical outcomes are still observed in...
3.
Tseng C, Fu Y, Ou D, Lu J, Hou H, Lin L
Cancer Gene Ther . 2023 Oct; 30(12):1691-1701. PMID: 37821641
Omipalisib (GSK2126458), a potent dual PI3K/mTOR inhibitor, is reported to exhibit anti-tumor effect in several kinds of cancers. More than 50% of acute myeloid leukemia (AML) patients display a hyperactivation...
4.
Chen P, Lin C, Wu C, Keak P, Liou J, Gao W, et al.
Chem Biol Interact . 2023 Sep; 385:110729. PMID: 37777166
Acute myeloid leukemia (AML) is a disease characterized by abnormal cell proliferation in the bone marrow and is the most common quickly progressive leukemia in adults. Pinostrobin, a flavonoid phytochemical,...
5.
Lee W, Tsai M, Tsai C, Tien F, Lo M, Tseng M, et al.
Blood Cancer J . 2023 Aug; 13(1):120. PMID: 37558665
Myelodysplastic syndromes (MDS) have varied prognoses and require a risk-adapted treatment strategy for treatment optimization. Recently, a molecular prognostic model (Molecular International Prognostic Scoring System [IPSS-M]) that combines clinical parameters,...
6.
Lo M, Cheng-Hong Tsai X, Lin C, Tien F, Kuo Y, Lee W, et al.
Am J Hematol . 2023 Mar; 98(5):760-769. PMID: 36861732
The European LeukemiaNet (ELN) recently proposed a revised recommendation for the diagnosis and management of acute myeloid leukemia (AML) in adults, recognized as ELN-2022. However, validation in a large real-world...
7.
Yao C, Agathangelidis A, Chuang S, Tsou H, Feng W, Liu T, et al.
Hemasphere . 2022 Dec; 6(12):e803. PMID: 36452029
Asian patientswith chronic lymphocytic leukemia (CLL) exhibit immunoglobulin heavy variable (IGHV) gene repertoires that are distinct from those observed in Western populations, and a higher proportion of Asian CLL patients...
8.
Chen K, Hsu C, Su Y, Yuan C, Lin L, Tsai J, et al.
Br J Cancer . 2022 Nov; 128(1):102-111. PMID: 36319846
Background: Prognosis of metastatic BRAF V600E mutant colorectal cancer (CRC) is poor, and the prognostic implications of immune contextures in the tumour microenvironment (TME) for CRC remain elusive. Methods: We...
9.
Wu J, Wu H, Wu S, Tsai H, Weng S, Lin K, et al.
Mol Cancer Res . 2022 May; 20(8):1222-1232. PMID: 35533307
Implications: This phosphoproteomic analysis and functional validation illuminated the phosphorylation of KAP1 at S473 as an important downstream BCR signaling event and a potential indicator for the success of ibrutinib...
10.
Chang H, Su K, Goodman S, Cheng W, Lin L, Yang Y, et al.
J Vis Exp . 2022 May; (182). PMID: 35532273
Uracil-DNA glycosylase (UDG) is a key component in the base excision repair pathway for the correction of uracil formed from hydrolytic deamination of cytosine. Thus, it is crucial for genome...